ATE341344T1 - Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer - Google Patents

Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer

Info

Publication number
ATE341344T1
ATE341344T1 AT97936407T AT97936407T ATE341344T1 AT E341344 T1 ATE341344 T1 AT E341344T1 AT 97936407 T AT97936407 T AT 97936407T AT 97936407 T AT97936407 T AT 97936407T AT E341344 T1 ATE341344 T1 AT E341344T1
Authority
AT
Austria
Prior art keywords
soluble polymer
polypeptides
water soluble
covalently bonded
terminal water
Prior art date
Application number
AT97936407T
Other languages
English (en)
Inventor
Ziping Wei
Sunitha Menon-Rudolph
Pradip Ghosh-Dastidar
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE341344T1 publication Critical patent/ATE341344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
AT97936407T 1996-08-02 1997-08-01 Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer ATE341344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2305096P 1996-08-02 1996-08-02

Publications (1)

Publication Number Publication Date
ATE341344T1 true ATE341344T1 (de) 2006-10-15

Family

ID=21812842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936407T ATE341344T1 (de) 1996-08-02 1997-08-01 Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer

Country Status (19)

Country Link
US (1) US6077939A (de)
EP (2) EP0964702B1 (de)
JP (1) JP4410852B2 (de)
KR (1) KR20000029673A (de)
CN (1) CN100471521C (de)
AT (1) ATE341344T1 (de)
AU (1) AU3908597A (de)
BR (1) BR9711009A (de)
CA (1) CA2262994A1 (de)
DE (1) DE69736780T2 (de)
DK (1) DK0964702T3 (de)
ES (1) ES2273373T3 (de)
IL (2) IL128229A0 (de)
NO (1) NO990465L (de)
NZ (1) NZ333993A (de)
PT (1) PT964702E (de)
RU (1) RU2199347C2 (de)
SI (1) SI0964702T1 (de)
WO (1) WO1998005363A2 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
MXPA03000311A (es) * 2000-07-12 2004-12-13 Gryphon Therapeutics Inc Produccion y uso de moduladores de receptor de quimiocina.
US7030218B2 (en) * 2000-09-08 2006-04-18 Gryphon Therapeutics Pseudo native chemical ligation
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1333036B1 (de) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modifiziertes erythropoietin
CN100528235C (zh) 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
EP1471871B1 (de) 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
WO2003045423A1 (en) 2001-11-28 2003-06-05 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
WO2003078959A2 (en) 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
CA2490360A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
EP1534269B1 (de) * 2002-07-19 2013-10-30 The General Hospital Corporation Oxim-konjugate und verfahren zu ihrer bildung und verwendung
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP1616003A4 (de) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1613261A4 (de) 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
US20050107297A1 (en) 2003-05-12 2005-05-19 Holmes Christopher P. Novel poly(ethylene glycol) modified compounds and uses thereof
NZ543934A (en) 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
EP1625156B1 (de) * 2003-05-12 2012-09-19 Affymax, Inc. An den erythropoietinrezeptor bindenden peptiden
EA010095B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новые пептиды, которые связываются с рецептором эритропоэтина
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
CN1826131A (zh) * 2003-05-30 2006-08-30 森托科尔公司 利用转谷氨酰胺酶形成新的促红细胞生成素缀合物
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
EP2641611A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2445948T3 (es) 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
US7368169B2 (en) * 2003-12-01 2008-05-06 Rutgers, The State University Of New Jersey Hydrazide compounds with angiogenic activity
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
CN1909930B (zh) 2004-01-21 2015-12-16 诺和诺德医疗保健公司 转谷氨酰胺酶介导的肽的接合
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
MXPA06014307A (es) * 2004-06-08 2007-03-12 Alza Corp Preparacion de conjugados macromoleculares por reaccion de condensacion de cuatro componentes.
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1814910A4 (de) * 2004-11-11 2009-04-29 Affymax Inc Neue am erythropoietinrezeptor bindende peptide
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
ES2821832T3 (es) * 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP1836314B1 (de) 2004-12-22 2012-01-25 Ambrx, Inc. Modifiziertes menschliches wachstumshormon
JP5425398B2 (ja) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
CA2594561C (en) 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
NZ555206A (en) 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
EP2314320A2 (de) 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur Abschirmung von funktionalen Stellen oder Epitopen von Proteinen
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888098A2 (de) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glykopegylierte erythropoetin-formulierungen
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CN103030690A (zh) 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
AU2006257792A1 (en) * 2005-06-13 2006-12-21 Mdrna, Inc. Transmucosal delivery of peptide derivatives
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CN101268098A (zh) * 2005-08-30 2008-09-17 诺沃-诺迪斯克保健股份有限公司 聚乙二醇化生长激素的液体制剂
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US7851438B2 (en) * 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
CA2655188A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
ES2529234T3 (es) * 2006-08-04 2015-02-18 Prolong Pharmaceuticals, LLC Eritropoyetina modificada
JP5840345B2 (ja) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CA2676820A1 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
WO2009003188A2 (en) * 2007-06-27 2008-12-31 Cedars-Sinai Medical Center N-terminal specific chemical labeling for proteomics applications
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
WO2009073977A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
EP3225248B1 (de) 2008-07-23 2023-06-07 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
EP2157432A1 (de) * 2008-08-15 2010-02-24 Qiagen GmbH Verfahren zur Analyse einer komplexen Probe durch Massenspektrometrie
KR101732054B1 (ko) 2008-09-26 2017-05-02 암브룩스, 인코포레이티드 비천연 아미노산 복제 의존성 미생물 및 백신
AU2009296397B2 (en) 2008-09-26 2012-11-08 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
JP5751641B2 (ja) 2009-05-06 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド メラノコルチン受容体結合コンジュゲート
PL2459224T3 (pl) * 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Rinder-Somatotropinpolypeptide und deren Verwendungen
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
DK2605789T3 (da) 2010-08-17 2019-09-16 Ambrx Inc Modificerede relaxinpolypeptider og anvendelser deraf
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102652836A (zh) * 2011-03-03 2012-09-05 华中科技大学同济医学院附属协和医院 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
AR087020A1 (es) 2011-07-01 2014-02-05 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
KR102172897B1 (ko) 2012-06-08 2020-11-02 서트로 바이오파마, 인크. 부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
PL3584255T3 (pl) 2012-08-31 2022-05-16 Sutro Biopharma, Inc. Modyfikowane aminokwasy zawierające grupę azydkową
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN102935236B (zh) * 2012-11-21 2015-08-26 武汉平华生物医药科技有限公司 一种具有p-糖蛋白抑制功能的抗肿瘤前药
BR112015022416A2 (pt) 2013-03-13 2017-10-24 Bioasis Technologies Inc fragmentos de p97 e seus usos
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
EA201690780A1 (ru) 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
SG11201804268RA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3433278A4 (de) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
WO2018175994A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CN111094462A (zh) 2017-12-26 2020-05-01 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
WO2019191482A1 (en) 2018-03-30 2019-10-03 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
JP7441826B2 (ja) 2018-09-11 2024-03-01 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド抱合物およびその使用
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN109400695B (zh) * 2018-10-31 2020-06-30 中南大学湘雅医院 一种多肽的修饰方法及应用
JP2022520792A (ja) 2019-02-12 2022-04-01 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2021067861A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Camptothecin peptide conjugates
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
MX2022012621A (es) 2020-04-10 2023-01-18 Seagen Inc Enlazadores de variantes de carga.
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
TW202246242A (zh) 2021-01-15 2022-12-01 美商西健公司 免疫調節抗體藥物結合物
AR124812A1 (es) 2021-02-03 2023-05-10 Seagen Inc Conjugados y compuestos inmunoestimulantes
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
WO2022251850A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2023083919A1 (en) 2021-11-09 2023-05-19 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a camptothecin moiety
WO2023083900A1 (en) 2021-11-09 2023-05-19 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a drug moiety
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE69023314T2 (de) 1989-04-26 1996-03-28 Fanuc Ltd Verfahren zur rotationssteuerung einer hauptwelle.
WO1991005867A1 (en) 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
JPH03151399A (ja) 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd 変異ヒトエリスロポエチン
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
CA2161651A1 (en) 1993-04-29 1994-11-10 Gregory F. Okasinski Erythropoietin analog compositions and methods
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU671914B2 (en) 1993-06-03 1996-09-12 Beckman Instruments, Inc. Sample segment
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates

Also Published As

Publication number Publication date
JP2000515553A (ja) 2000-11-21
KR20000029673A (ko) 2000-05-25
CN1226176A (zh) 1999-08-18
SI0964702T1 (sl) 2007-02-28
PT964702E (pt) 2006-12-29
CA2262994A1 (en) 1998-02-12
WO1998005363A2 (en) 1998-02-12
EP1731174A3 (de) 2007-01-17
WO1998005363A3 (en) 1998-05-07
AU3908597A (en) 1998-02-25
IL128229A0 (en) 1999-11-30
DE69736780D1 (de) 2006-11-16
DK0964702T3 (da) 2007-01-08
NO990465D0 (no) 1999-02-01
ES2273373T3 (es) 2007-05-01
EP1731174A2 (de) 2006-12-13
US6077939A (en) 2000-06-20
DE69736780T2 (de) 2007-09-06
BR9711009A (pt) 1999-08-17
IL128229A (en) 2007-07-04
NO990465L (no) 1999-03-23
NZ333993A (en) 2000-01-28
CN100471521C (zh) 2009-03-25
EP0964702A2 (de) 1999-12-22
JP4410852B2 (ja) 2010-02-03
RU2199347C2 (ru) 2003-02-27
EP0964702B1 (de) 2006-10-04

Similar Documents

Publication Publication Date Title
ATE341344T1 (de) Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
DE69841038D1 (de)
WO1998002454A3 (en) Conjugates of soluble peptidic compounds with membrane-binding agents
GR3029740T3 (en) Fragments of prion proteins.
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO1997040854A3 (en) Polypeptide conjugates for transporting substances across cell membranes
EP1077217A3 (de) Neuroaktive Peptide und deren Verwendung
WO2001004265A3 (en) C-terminal protein tagging
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
BR9812490A (pt) Sistema de reconhecimento modular endereçável, sua preparacão e uso
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
AU3186397A (en) Prion protein binding proteins and uses thereof
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
WO2000047739A3 (en) Autoantigens for the diagnostic of endometriosis
CA2112701A1 (en) Proteins s polypeptides and uses thereof
NO974713L (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
DK0792291T3 (da) Protein, der påvirker KATP-kanaler
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
EP1186662A3 (de) Prionbindendes Proteine und deren Verwendungen
AU2525597A (en) Monoclonal antibodies binding human growth hormone (hgh)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0964702

Country of ref document: EP